Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients

International Journal of Rheumatic Diseases

Volumn 15, Issue 3, 2012, Pages 315-321

  Tragulpiankit, Pramote ^a   Chulavatnatol, Suvatna ^a   Rerkpattanapipat, Ticha ^a   Janwityanujit, Suchela ^a   Somjarit, Suthatip ^a   Sirikhedgon, Uamporn ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Adverse drug events; Osteoarthritis; Outpatients; Prevalence; Rheumatoid arthritis; Thailand

Indexed keywords

CELECOXIB; CHLOROQUINE; CYCLOPHOSPHAMIDE; DICLOFENAC; DOXAZOSIN; ETANERCEPT; FLUOXETINE; GLIBENCLAMIDE; HYDROXYCHLOROQUINE; INDOMETACIN; LEFLUNOMIDE; LUMIRACOXIB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPROXEN; PREDNISOLONE; SALAZOSULFAPYRIDINE; TRAMADOL; TUBERCULOSTATIC AGENT;

ADULT; AGED; ARTICLE; BILIARY TRACT DISEASE; BLOOD DISEASE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG INDUCED DISEASE; ENDOCRINE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INTERVIEW; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; OSTEOARTHRITIS; OUTPATIENT; PEPTIC ULCER; PERIPHERAL NEUROPATHY; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SKIN APPENDAGE DISEASE; SKIN DISEASE; URINARY TRACT DISEASE; VISUAL DISORDER;

ADULT; AGED; AMBULATORY CARE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; PREVALENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THAILAND;

EID: 84862520517     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2012.01716.x     Document Type: Article

References (25)

1. Chopra A, Abdel-Nasser A (2008) Epidemiology of rheumatic musculoskeletal disorders in the developing world. Best Pract Res Clin Rheumatol 22, 583-604.
2. Chaiamnuay P, Darmanwan J, Muirden KD, Assawatanabodee P (1998) Epidemiology of rheumatic disease in rural Thailand: a WHO-ILAR COPCORD study. Community oriented programme for the control of rheumatic disease. J Rheumatol 25, 1382-7.
3. Woolf AD, Pfleger B (2003) Burden of major musculoskeletal conditions. Bull World Health Organ 81, 646-56.
4. Schuna AA (2008) Rheumatoid arthritis. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L (eds) Pharmacotherapy: A Pathophysiologic Approach. 7th edn, pp 1505-18. McGrawHill, New York.
5. Hasnsen KE, Elliott ME (2005) Osteoarthritis. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L (eds) Pharmacotherapy: A Pathophysiologic Approach. 6th edn, pp 1692-8. McGrawHill, New York.
6. Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376, 1094-108.
7. Das SK, Farooqi A (2008) Osteoarthritis. Best Pract Res Clin Rheumatol 22, 657-75.
8. Ong CK, Lirk P, Tan CH, Seymour RA (2007) An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res 5, 19-34.
9. Pirmohamed M, James S, Meakin S, et al. (2004) Adverse drug reactions as cause of admission to hospital: prospective analphylaxis of 18, 820 patients. BMJ 329, 15-9.
10. Edwards IR (2005) What are the real lessons from Vioxx? Drug Saf 28, 651-8.
11. Laine L, White WB, Rostom A, Hochberg M (2008) COX-2 selective inhibitors in the treatment of osteoarthritis. Semin Arthritis Rheum 38, 165-87.
12. Saag KG, Teng GG, Patkar NM, et al. (2008) American college of rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59, 762-84.
13. Nebeker JR, Barach P, Samore MH (2004) Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med 140, 795-801.
14. Thomsen LA, Winterstein AG, Sondergaard B, Haugbolle LS, Melander A (2007) Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother 41, 1411-26.
15. Gandhi TK, Weingart SN, Borus J, et al. (2003) Adverse drug events in ambulatory care. N Engl J Med 348, 1556-64.
16. Gurwitz JH, Field TS, Harrold LR, et al. (2003) Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 289, 1107-16.
17. Ganjavi H, Herrmann N, Rochon PA, et al. (2007) Adverse drug events in cognitively impaired elderly patients. Dement Geriatr Cogn Disord 23, 395-400.
18. Bourgeois FT, Mandl KD, Valim C, Shannon MW (2009) Pediatric adverse drug events in the outpatient setting: an 11-year national analysis. Pediatrics 124, e744-50.
19. Hartwig SC, Siegel J, Schneider PJ (1992) Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 49, 2229-32.
20. Schumock GT, Thornton JP (1992) Focusing on the preventability of adverse drug reactions. Hosp Pharm 27, 538.
21. Danan G, Benichou C (1993) Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 46, 1323-30.
22. Benichou C, Danan G, Flahault A (1993) Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 46, 1331-6.
23. Bates DW, Cullen DJ, Laird N, et al. (2005) Incidence of adverse drug events and potential adverse drug events. JAMA 274, 29-34.
24. Agbabiaka TB, Savovic J, Ernst E (2008) Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf 31, 21-37.
25. Rommers MK Teepe-Twiss IM, Guchelaar HJ (2007) Preventing adverse drug events in hospital practice: an overview. Pharmacoepidemiol Drug Saf 16 1129-35.